Progress of patients with pulmonary atresia after systemic to pulmonary arterial shunts

Ann Thorac Surg. 1991 Mar;51(3):401-7. doi: 10.1016/0003-4975(91)90853-i.

Abstract

Between February 1980 and June 1987, 42 shunts were placed in 39 infants with pulmonary atresia: 33 were modified Blalock-Taussig shunts with polytetrafluoroethylene (PTFE) and 9 were classic Blalock-Taussig shunts. There were four hospital deaths not related to the shunts. The remaining 35 patients were followed up for 1.6 months to 6.3 years (mean, 24.7 +/- 18 months). Repeat cineangiocardiographic studies revealed stenosis or distortion of the pulmonary arteries related to the site of the shunt in 11/22 patients (50%) with PTFE shunts and in 1/6 (17%) with classic Blalock-Taussig shunts; the stenosis was severe in only 1 patient. Mean increase in the pulmonary arterial index in the group with classic Blalock-Taussig shunts was 117 +/- 52 mm2/m2 (not significant) and in the group with PTFE shunts, 158 +/- 21 mm2/m2 (p less than 0.001). Late shunt occlusion occurred in 1 patient 23 months postoperatively. Thereafter, shunt patency rate remained at 94% +/- 6%. At the end of 1 year 81% +/- 7% of patients were judged to have adequate palliation, but between 2 and 3 years, only 60% +/- 10%. Univariate analysis showed that after 2 years the ranking order for successful palliation was classic Blalock-Taussig, 5-mm PTFE, and 4-mm PTFE shunts, but differences did not achieve statistical significance.

MeSH terms

  • Abnormalities, Multiple / mortality
  • Abnormalities, Multiple / surgery
  • Anastomosis, Surgical / adverse effects
  • Angiocardiography
  • Arterial Occlusive Diseases / etiology
  • Arterial Occlusive Diseases / mortality
  • Blood Vessel Prosthesis
  • Cineangiography
  • Heart Defects, Congenital / mortality
  • Heart Defects, Congenital / surgery
  • Humans
  • Infant
  • Infant, Newborn
  • Palliative Care*
  • Polytetrafluoroethylene
  • Prognosis
  • Pulmonary Artery / diagnostic imaging
  • Pulmonary Artery / surgery*
  • Pulmonary Valve / abnormalities*
  • Pulmonary Valve / surgery
  • Reoperation
  • Subclavian Artery / surgery*
  • Survival Rate
  • Vascular Patency

Substances

  • Polytetrafluoroethylene